GSK loses patent infringement appeal over slow-release Panadol
Intellectual Property 2018-05-11 9:32 pm By Christine Caulfield | Melbourne
Please login to bookmark Close

A full bench of the Federal Court has dismissed an appeal by drug giant GlaxoSmithKline in a patent infringement case it brought over planned generic versions of its sustained-release Panadol.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au